tiprankstipranks
I-MAB (IMAB)
NASDAQ:IMAB
US Market

I-MAB (IMAB) AI Stock Analysis

Compare
298 Followers

Top Page

IM

I-MAB

(NASDAQ:IMAB)

45Neutral
The overall stock score of 45 reflects I-MAB's substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.
Positive Factors
Resource Allocation
I-Mab recently announced it will be prioritizing its remaining resources on givastomig, a CLDN18.2x4-1BB bispecific antibody.
Safety Profile
Givastomig showed a standout safety profile with no dose-limiting toxicity observed at higher doses and common adverse events being mild.
Negative Factors
Pipeline Valuation
Analyst is lowering the pipeline valuation from $350M to $200M.

I-MAB (IMAB) vs. S&P 500 (SPY)

I-MAB Business Overview & Revenue Model

Company DescriptionI-Mab is a clinical stage biopharmaceutical company. It engages in discovering, developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zhang Zang on June 30, 2016 and is headquartered in Pudong, China.
How the Company Makes MoneyI-MAB primarily generates revenue through partnerships and collaborations with other pharmaceutical companies for the development and commercialization of its drug candidates. The company may receive upfront payments, milestone payments, and royalties from these partnerships as its drug candidates progress through clinical trials and reach the market. Additionally, I-MAB might gain revenue from licensing its proprietary technologies and intellectual property to other entities. Significant partnerships with global pharmaceutical companies facilitate the advancement of its pipeline, contributing to its earnings potential.

I-MAB Financial Statement Overview

Summary
I-MAB faces substantial financial challenges, particularly in terms of profitability and cash flow generation. Although the company benefits from a strong liquidity position and low leverage, its ability to generate positive earnings and cash flows remains a concern. The volatility in revenue and consistent losses highlight the need for strategic adjustments to improve financial performance.
Income Statement
20
Very Negative
The company's income statement indicates significant challenges, with substantial negative net income and EBIT margins over recent years. Although there was a positive revenue figure in 2023, the revenue growth has been erratic, with a substantial decline from 2020 to 2022 followed by a modest recovery. Gross profit margins have been inconsistent, which, coupled with negative net profit and EBIT margins, underscores profitability issues.
Balance Sheet
50
Neutral
The balance sheet shows a strong equity base relative to liabilities, with a debt-to-equity ratio remaining low due to minimal debt levels. However, the equity ratio has been declining, indicating diminishing equity relative to total assets. The company maintains a significant cash position, which is a positive sign of liquidity.
Cash Flow
30
Negative
Cash flow analysis reveals persistent negative free cash flows, indicating challenges in generating sufficient cash from operations. The absence of operating cash flow data for 2023 makes it difficult to assess the recent cash generation ability. Historical trends show negative operating cash flow, impacting the overall cash flow position negatively.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
7.99M27.64M-221.56M88.03M1.54B30.00M
Gross Profit
7.99M27.64M-248.80M41.59M1.54B30.00M
EBIT
-579.25M-1.24B-1.97B-2.07B155.57M-1.46B
EBITDA
-566.93M-1.21B-1.94B-2.06B168.31M-1.46B
Net Income Common Stockholders
-667.77M-1.47B-2.51B-2.33B470.92M-1.49B
Balance SheetCash, Cash Equivalents and Short-Term Investments
2.28B2.29B3.45B4.28B4.79B1.17B
Total Assets
2.61B2.61B4.07B5.63B6.33B1.74B
Total Debt
133.87M18.89M74.99M112.45M13.60M132.50M
Net Debt
-2.01B-2.01B-3.14B-3.41B-4.75B-1.00B
Total Liabilities
894.81M894.81M1.07B1.04B706.65M3.77B
Stockholders Equity
1.72B1.72B3.01B4.59B5.63B-2.03B
Cash FlowFree Cash Flow
0.00-1.32B-1.15B-1.00B425.55M-880.22M
Operating Cash Flow
0.00-1.10B-973.09M433.56M-867.98M
Investing Cash Flow
0.00102.52M458.38M-727.21M-201.90M212.46M
Financing Cash Flow
0.007.57M42.36M593.92M3.44B152.71M

I-MAB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.82
Price Trends
50DMA
0.97
Negative
100DMA
1.02
Negative
200DMA
1.21
Negative
Market Momentum
MACD
-0.04
Positive
RSI
35.17
Neutral
STOCH
23.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMAB, the sentiment is Negative. The current price of 0.82 is below the 20-day moving average (MA) of 0.91, below the 50-day MA of 0.97, and below the 200-day MA of 1.21, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 35.17 is Neutral, neither overbought nor oversold. The STOCH value of 23.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMAB.

I-MAB Risk Analysis

I-MAB disclosed 91 risk factors in its most recent earnings report. I-MAB reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

I-MAB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
$12.82B11.4223.16%30.43%82.29%
59
Neutral
$3.88B-31.41%49.59%24.92%
ONONC
56
Neutral
$27.60B-18.77%54.96%27.51%
49
Neutral
$6.84B0.05-53.14%2.48%24.49%-3.26%
45
Neutral
$61.84M-39.60%
42
Neutral
$115.74M-54.21%-78.55%-0.92%
42
Neutral
$13.55M-151.46%-95.23%-325.89%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IMAB
I-MAB
0.84
-0.96
-53.33%
FATE
Fate Therapeutics
0.94
-6.29
-87.00%
AFMD
Affimed
0.88
-3.52
-80.00%
ONC
BeiGene
254.57
85.67
50.72%
ZLAB
Zai Lab
36.14
16.59
84.86%
GMAB
Genmab
19.96
-10.34
-34.13%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.